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Many viruses induce hepatitis in humans, high-
lighting the need to understand the underlying mech-
anisms of virus-induced liver pathology. The murine
coronavirus, mouse hepatitis virus (MHV), causes
acute hepatitis in its natural host and provides
a useful model for understanding virus interaction
with liver cells. The MHV accessory protein, ns2,
antagonizes the type I interferon response and
promotes hepatitis.We show that ns2 has 20,50-phos-
phodiesterase activity, which blocks the interferon
inducible 20,50-oligoadenylate synthetase (OAS)-
RNase L pathway to facilitate hepatitis development.
Ns2 cleaves 20,50-oligoadenylate, the product of
OAS, to prevent activation of the cellular endoribonu-
clease RNase L and consequently block viral RNA
degradation. An ns2mutant viruswas unable to repli-
cate in the liver or induce hepatitis in wild-type mice,
but was highly pathogenic in RNase L deficient mice.
Thus, RNase L is a critical cellular factor for protec-
tion against viral infection of the liver and the result-
ing hepatitis.
INTRODUCTION
Many viral infections induce acute and/or chronic liver pathology
in humans, for which there are often no known effective therapies
or vaccines. There is little known about the early virus-host inter-
actions that determine whether an infection is established, high-
lighting the need to understand mechanisms regulating the
pathogenesis of viral hepatitis. The liver is constantly exposed
to intestinal derived antigens present in the blood circulating
through the liver sinusoids and, therefore, has evolved a unique
immune environment that is relatively tolerant to foreign antigens
and permissive to chronic infections (Crispe, 2009; Neumann-
Haefelin et al., 2007). Thus, the innate immune response is
a particularly important defense against pathogen invasion ofCell Hthe liver. Type I interferon (IFN) is the first line of defense available
to restrict viral infection including infections with human hepatitis
viruses (Garcı´a-Sastre and Biron, 2006; Qu and Lemon, 2010).
Kupffer cells (liver macrophages) found in the liver sinusoids
are among the first cells to encounter viruses and as such, along
with endothelial cells present a barrier that must be breached in
order to access hepatocytes in the liver parenchyma (Crispe,
2009). Indeed, it has been reported that IFN signaling in macro-
phages is crucial for control of hepatitis induced by mouse
hepatitis virus (Cervantes-Barraga´n et al., 2009) and lymphocytic
choriomeningitis virus (Lang et al., 2010).
Type I IFN, primarily IFN-a/b, produced by virus-infected
cells, induces expression of over four hundred interferon-stimu-
lated genes (ISGs), whose products cooperate to induce an
antiviral state. One potent antiviral IFN induced activity is the
20,50-oligoadenylate synthetase-ribonuclease L (OAS-RNase L)
pathway (Sadler and Williams, 2008) (Figure 1). After infection,
IFNs induce a group of OAS genes whose products are acti-
vated by viral double-stranded RNA (dsRNA). OAS uses ATP
to generate the 20,50-linked oligoadenylates with the structures
[px5
0A(20p50A)n; x = 1–3; nR 2 (2-5A)]. 2-5A binds to the ubiqui-
tous cellular endoribonuclease RNase L, causing inactive
RNase L monomers to form activated dimers (Dong and Silver-
man, 1995). RNase L cleaves single-stranded regions of both
viral and cellular messenger RNA (mRNA), leading to inhibition
of viral replication and protein synthesis (Silverman, 2007). In
addition, detection of the newly generated short RNAs by
cellular pattern recognition receptors, MDA5 and RIG-I, further
enhances IFN production and the ensuing antiviral activities
(Malathi et al., 2007). The concentration of 2-5A is believed to
be the primary factor controlling RNase L activation. The cellular
enzyme 20-phosphodiesterase (20-PDE, also known as PDE12)
has been proposed to reduce or prevent 2-5A-mediated activa-
tion of RNase L by degrading 2-5A, presumably to prevent
excessive tissue damage caused by the effects of RNase L
(Kubota et al., 2004). The antiviral activity of the OAS-RNase L
pathway has been demonstrated during infections of mice
with numerous RNA and DNA viruses (Flodstro¨m-Tullberg
et al., 2005; Li et al., 1998; Samuel et al., 2006; Scherbik
et al., 2006; Washenberger et al., 2007; Xiang et al., 2002;
Zhou et al., 1997).ost & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier Inc. 607
Figure 1. The Interferon-Induced OAS-RNase L Pathway
After infection, viral RNA is detected by pattern recognition receptors RIG-I
and MDA5, resulting in the induction of IFN-a/b, which in turn induces ISGs,
including OAS. OAS is activated by dsRNA to produce 2-5A, which activates
RNase L. RNase L degrades cellular and viral RNA producingmore RNA that is
recognized by MDA5 and RIG-I, resulting in enhanced IFN induction. 20-PDE
cleaves 2-5A and inhibits the activation of RNase L. MHV ns2, like the cellular
enzyme 20-PDE, is a 20,50-phosphodiesterase. OAS, 20-50-oligoadenylate
synthetase; 2-5A, 20,50 oligoadenylate; 20-PDE, 20-phosphodiesterase.
Figure 2. MHV Replication Is Not Inhibited by RNase L Signaling
(A–C) BMMs fromB6 or RNase L/micewere infectedwithMHV-A59, SeV, or
EMCV (1 PFU/cell). At the indicated time points, RNA was isolated from cell
lysates and viral mRNA expression quantified by qRT-PCR (n = 3). Relative
viral mRNA expression levels were expressed as 2DCT, relative to b-actin
mRNA [DCT = CT(gene of interest) – CT(b-actin)].
(D) Cells infected with MHV-A59 were lysed by freeze-thawing and titers
determined by plaque assay (n = 3).
See also Table S1.
Cell Host & Microbe
RNase L Antagonism Is Required for Viral HepatitisHepatitis caused by the murine coronavirus, mouse hepatitis
virus (MHV), is an acute disease induced in the natural host
and provides a convenient and valuablemodel for understanding
the interaction of virus with liver cells (Weiss and Leibowitz,
2011). Previous studies using reverse genetics and MHV strains
with different tropisms demonstrated that events that occur after
viral entry play a crucial role in the likelihood of liver invasion and
the development of hepatitis (Navas and Weiss, 2003). Indeed,
we recently reported that MHV accessory protein ns2 confers
the ability to antagonize the type I IFN antiviral response in
macrophages and that this is required for efficient viral replica-
tion in the liver and the development of hepatitis (Zhao et al.,
2011). Based on sequence homology to cellular phosphodiester-
ases, ns2 had been predicted to be a cyclic phosphodiesterase
(Mazumder et al., 2002; Snijder et al., 2003). We show here that
ns2 has in fact a 20,50-phosphodiesterase activity that can down-
regulate intracellular levels of 2-5A, thereby preventing the acti-
vation and antiviral activity of RNase L. Our results underscore
the importance of the OAS-RNase L pathway in vivo for protec-
tion of the host from developing viral hepatitis.
RESULTS
MHV A59 Resists RNase L Activity
MHV differs from many other viruses in that it stimulates type I
IFN production in only limited cell types, primarily in macro-
phages (Roth-Cross et al., 2008) and plasmacytoid dendritic
cells (Cervantes-Barragan et al., 2007). Furthermore MHV
displays cell type-specific sensitivity to the antiviral effects of
IFN treatment, with macrophage lineage cells being most
successful in restricting MHV replication (Rose and Weiss,608 Cell Host & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier2009; Zhao et al., 2011). We also observed that MHVwas unable
to prevent IFN induction by a coinfecting virus and was also
unable to protect a coinfecting virus from the effects of IFN
(Roth-Cross et al., 2007). Thus, we reasoned that MHV is unable
to subvert major IFN signaling pathways, but rather may interfere
with one or more IFN-induced antiviral activities. Indeed,
a previous study showed that MHV-A59 infection does not
promote RNase L-mediated degradation of 18S and 28S ribo-
somal RNA (rRNA) in HeLa cells (Ye et al., 2007), suggesting
that the OAS-RNase L pathway may be downregulated. To
more directly evaluate the role of RNase L in MHV replication,
we compared the replication of wild-type A59 in bone-marrow
derived macrophages (BMMs) from wild-type C57BL/6 (B6)
mice or from mice genetically ablated for RNase L expression
[RNase L/ (B6)]. The kinetics of accumulation of A59 genome
RNA were indistinguishable in the two cell types (Figure 2A), as
was the extent of infectious virus replication (Figure 2D).
In contrast, the genome RNA levels of Sendai virus (SeV)
and encephalomyocarditis virus (EMCV) were approximately
16-fold and 64-fold higher at 12 hr after infection in BMMs
derived from RNase L/ mice, compared with B6 (Figures 2B
and 2C, respectively). These results indicate that RNase L
activity restricts the replication of both SeV and EMCV but not
that of MHV A59.Inc.
Figure 3. The MHV ns2 Mutant Replicates to the Same Extent as WT
Virus in BMM from RNase L–/– but Not PKR–/– mice
(A and B) BMMs, derived from RNase L/ or PKR/ mice were infected
(0.01 PFU/cell). At the indicated times, titers of viruses in the cell lysates
combined with supernatants were determined by plaque assay (n = 3).
(C) BMMs derived from B6 or RNase L/ mice were infected (MOI = 0.01
PFU/cell). At 48 hr p.i., the cells were stained with anti-MHV N antibody and
Hoechst. The scale bar represents 100 mm.
See also Figure S1.
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We showed previously that A59 ns2 antagonizes the IFN-
signaling pathway in macrophage lineage cells (Zhao et al.,
2011). Furthermore the A59 mutant virus, ns2-H126R, carrying
a single amino acid substitution in a predicted phosphodies-
terase catalytic His residue (Mazumder et al., 2002; Roth-Cross
et al., 2009; Snijder et al., 2003), is attenuated for replication in
macrophages (Zhao et al., 2011). Thus, we hypothesized that
ns2 could protect the viral genome RNA from RNase L-mediated
degradation through its phosphodiesterase activity, which might
cleave 2-5A, thereby reducing the level of inducer of RNase L
activity. To test this hypothesis, we first compared the replication
kinetics of A59 and ns2-H126R in BMMs derived from B6 and
RNase L/ mice. Along with robust replication of A59 in B6
BMMs (Figure 3A), we observed extensive lysis of most of the
cells by 48 hr postinfection (p.i.), while most of ns2-H126R-Cell Hinfected BMMs remained intact (Figure 3C). The few cells
left intact after A59 infection expressed viral antigen, while
there were small numbers of cells expressing viral antigen
after ns2-H126R infection. In contrast, in RNase L/ BMMs,
ns2-H126R recovered the ability to replicate efficiently, with
similar kinetics (Figure 3A) and induced similar wide spread cell
lysis as A59 (Figure 3C). Similar results were obtained for two
other mutants carrying single amino acid substitutions in ns2,
H46A, and L94P (Figure S1 available online). These data suggest
that ns2 confers the ability to antagonize the antiviral activities of
RNase L.
To gain further insight into the mechanism of ns2 action, we
compared the replication of A59 and ns2-H126R in mice genet-
ically ablated for expression of PKR (protein kinase R), a potent
antiviral mediator that like OAS is bound and activated by
dsRNA (Sadler and Williams, 2008). A59 replicated to 10-fold
higher titer in PKR/ as compared to B6 BMMs, indicating
that MHV is sensitive to the antiviral effects of PKR. However,
the replication kinetics of ns2-H126R in PKR/ BMMs were
the same as in B6 BMMs (Figure 3B), indicating that ns2 does
not antagonize PKR, but rather specifically inhibits the OAS-
RNase L pathway. Together with the results obtained in the
RNase L/ BMMs (Figure 3A), these data imply that ns2 acts
through a mechanism other than that employed by other viral
proteins, including vaccinia E3L (Chang et al., 1992; Xiang
et al., 2002) and influenza ns1 (Lu et al., 1995; Min and Krug,
2006), which inhibit both OAS and PKR activity by binding and
sequestering dsRNA.
Ns2 Inhibits RNase L Cleavage by Decreasing 2-5A
Levels
In order to compare the extent of RNaseL activity during A59 and
ns2-H126R infection, we compared the state of cleavage of
rRNA in B6 BMMs infected with either ns2-H126R or A59. RNA
chip analysis of infected BMMs showed that ns2-H126R induced
obvious rRNA cleavage at 9 and 12 hr p.i. In contrast, A59 did not
induce rRNA cleavage above background even at the later time
points, indicating that ns2 efficiently inhibits rRNA cleavage (Fig-
ure 4A). As expected, neither virus induced rRNA cleavage in
RNase L/ BMMs (Figure S2A), confirming the cleavage was
RNase L mediated.
Latent RNase L is activated by 20,50-linked oligoadenylate
(2-5A), which is synthesized by OAS upon activation with dsRNA
(Silverman, 2007). To further investigate whether ns2 directly
inhibits accumulation of 2-5A, through its predicted phosphodi-
esterase activity (Mazumder et al., 2002), we measured intracel-
lular levels of 2-5A with A59 or ns2-H126R in BMMs derived from
B6 (Figure 4C) and RNase L/ (Figure 4D) mice. In both B6 and
RNase L/ BMMs, the concentration of 2-5A in ns2-H126R-
infected cells was significantly higher than that in A59-infected
cells. It should be noted that the 2-5A concentration in RNase
L/ BMMs, as measured by activation of RNase L in a fluores-
cence resonance energy transfer (FRET)-based assay (see the
Experimental Procedures) after infection with either viral strain
wasmuch lower than that in virus-infected B6 BMMs (Figure 4D),
probably because induction of optimal OAS levels is dependent
on an active OAS-RNase L pathway (Malathi et al., 2007).
To directly assess the effects of ns2 on the level of 2-5A,
we transfected ns2- and ns2-H126R-expressing plasmidsost & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier Inc. 609
Figure 4. MHV ns2 Protein Inhibits Ribo-
somal RNADegradation aswell as Accumu-
lation of 2-5A in Infected BMMs and in 293T
Cells Induced with Poly(I:C)
(A) B6 BMMs were infected (1 PFU/cell). At the
indicated times, RNA was purified and analyzed
on a Bioanalyzer. The positions of 18S and 28S
rRNA are indicated.
(B) 293T cells were transfectedwith pCAGGS (pC),
pC-ns2, or pC-ns2-H126R and 24 hr later were
transfected with 10 mg/ml poly(I:C). Four hours
later, RNA was purified and analyzed on a Bio-
analyzer.
(C and D) 2-5A was isolated from virus-infected
BMMs described in (A) derived from B6 mice at 6
and 9 hr p.i (C) or RNase L/ mice at 9 hr p.i. (D)
and analyzed by FRET. Error bars represent the
SEM (n = 3). Asterisks indicate that differences are
statistically significant (*p < 0.05 and***p < 0.001).
(E)2-5A fromtransfected293Tcells described in (B)
was isolated and quantified by FRET. Error bars
represent the SEM (n = 3). Asterisks indicate that
differencesarestatistically significant (***p<0.001).
See also Figure S2.
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clonal antibody (obtained from Dr. Stuart Siddell, University of
Bristol) demonstrated similar expression levels of WT and
H126R mutant ns2 (Figure S2B). The OAS-RNase L pathway
was subsequently activated in ns2-expressing cells by treatment
with IFN and transfection of poly(rI):poly(rC) [poly(I:C)], which
mimics naturally occurring dsRNA in activating OAS activity,
and the level of RNase L mediated cleavage of rRNA assessed.
The expression of ns2 but not ns2-H126Rmutant protein in 293T
cells decreased the extent of rRNA cleavage as compared with
empty vector-transfected cells (Figure 4B). In addition, the level
of 2-5A in ns2-transfected cells was significant lower (p < 0.001)
than that in empty vector- or ns2-H126R mutant-transfected
cells (Figure 4E). Taken together, these results demonstrate
that ns2 inhibits RNase L-induced cleavage by limiting the
amount of available 2-5A.
Ns2 Degrades 2-5A into ATP and AMP
Previous studies reported that the cellular protein 20-phosphodi-
esterase (20-PDE) degrades 2-5A into AMP and ATP and was
presumed to regulate the level of RNase L activity (Kubota
et al., 2004). Since ns2 was predicted to have phosphodies-
terase activity, we hypothesized that ns2 could display a similar
enzymatic activity to 20-PDE and directly cleave 2-5A, thus
reducing the activation of RNase L. To test this hypothesis, we
expressed ns2, ns2-H126R, and murine 20-PDE in E. coli and
purified the recombinant proteins as described in the Supple-
mental Experimental Procedures. Each protein was incubated
with trimer 2-5A [(20-50)p3A3], and at several time points the610 Cell Host & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier Inc.degradation products were monitored
by a high-performance liquid chromatog-
raphy (HPLC) assay. ns2 and murine
20-PDE, but not ns2-H126R, degraded
2-5A to the final products of AMP and
ATP (Figures 5A–5C). As confirmed byFRET assays (Thakur et al., 2005), the quantity of (20-50)p3A3
remaining was significantly decreased after incubation with
both ns2 and murine 20-PDE but not ns2-H126R inactive protein
(Figure 5D). These findings demonstrated that ns2 has specificity
for 20,50-phosphodiester bonds and can directly degrade 2-5A
with similar kinetics as 20-PDE.
Inhibition of the OAS-RNase L Pathway Is Required for
MHV Replication and Spread In Vivo
Our previous studies demonstrated that after intrahepatic (IH)
inoculation of A59, viral replication is robust in the liver by
3 days postinfection (d.p.i.), peaks at 5 d.p.i., and is mostly
cleared by 7 d.p.i. (Navas et al., 2001; Roth-Cross et al., 2009).
In contrast, ns2-H126R replicates minimally in the liver (Roth-
Cross et al., 2009; Zhao et al., 2011). However, in mice depleted
of macrophages prior to infection, ns2-H126R replication and
induction of hepatitis were significantly enhanced, approaching
that of A59 (Zhao et al., 2011). Taking these in vivo data in combi-
nation with the finding that ns2-H126R replicates minimally in B6
BMMs (Figure 3A) (Zhao et al., 2011), we speculated that the
ability to replicate in Kupffer cells (liver macrophages) was
a prerequisite for spread of virus into the liver parenchyma and
for the consequent development of hepatitis. Since ns2-H126
recovers the ability to replicate in RNase L/ BMMs (Figure 3A),
we predicted that the ns2 mutant virus would also replicate and
spread in the absence of RNase L activity in vivo. For testing of
this hypothesis, both B6 and RNase L/ mice were inoculated
IH with 200 PFU of either A59 or ns2-H126R and virus titers in
the liver were quantified. In B6 mice, A59 replicated to high titers
Figure 5. MHV ns2 Cleaves (20-50)p3A3 into AMP
and ATP In Vitro
(A–C) Purified (20-50)p3A3 was incubated with 10 mg/ml of
purified MHV ns2, ns2-H126R, or murine 20-PDE. At the
times indicated, the reactions were stopped; (20-50)p3A3
and its degradation products were analyzed by HPLC.
(D) The amount of uncleaved (20-50)p3A3 remaining was
determined by FRET. Error bars represent the SEM (n = 3).
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of detection. In contrast, in RNase L/ mice, ns2-H126R
reached titers, comparable to those attained by A59 (Figure 6A),
reflecting that wild-type ns2 expression is not necessary for effi-
cient replication in the absence of RNase L expression. Notably,
there was no significant difference in A59 titers between livers
from B6 mice and RNase L/ mice, indicating that ns2 is effi-
cient at antagonizing RNase L activation in B6mice. Surprisingly,
however, by 7 d.p.i., there were striking differences in viral clear-
ance between B6 and RNase L/mice. While both viruses were
nearly cleared from the liver of B6 mice at 7 d.p.i., there were still
considerable titers of both A59 and ns2-H126R in the livers of
RNase L/ mice (Figure 6A).
Consistent with viral titers, in B6 mice, A59 expresses abun-
dant viral antigen at 5 d.p.i., which is mostly cleared at 7 d.p.i.,
while ns2-H126R expresses minimal if any viral antigen. In
contrast, in RNaseL/ mice, both viruses express viral antigen
at 5 d.p.i. to a similar extent as in B6 mice (Figure 6B). However
instead of clearing virus at 7 d.p.i., both viruses expressed
increase viral antigen compared to 5 d.p.i. These data indicate
that ns2-mediated antagonism of RNase L activation confers
the ability to replicate in the liver, but complete genetic ablation
of RNase L expression in mice has additional effects on viral
clearance.
The patterns of replication of A59 and ns2-H126R in the
spleen, lung, and kidney of B6 mice were similar to those in
the liver; ns2-H126R replicated minimally, while A59 replicatedCell Host & Microbe 11,efficiently, although not to as high titers as in
the liver (Figure 6A). There were no significant
differences between A59 and ns2-H126R repli-
cation in the spleen, lung, and kidney of RNase
L/ mice at all times tested (Figure 6A), and
viral antigen expression in the spleen confirmed
that the viral replication and spread for ns2-
H126Rwere similar to those of A59 in the RNase
L/ mice (Figure S3A).
As in comparison of replication in the liver, B6
and RNase L/ mice showed no difference in
infectious A59 titers in the lung and kidney at
3 and 5 d.p.i. However, the A59 titer in the
spleen at both 3 and 5 d.p.i of RNase L/
mice was 10-fold higher than that in B6. This
may be at least in part due to the previously
reported reduced level of apoptosis in the
spleen of RNase L/ mice (Zhou et al., 1997).
Though not statistically significant, the low,
but detectable titers of virus at 7 d.p.i. in the
spleen, lung, and kidney of RNase L/ mice
were all higher than in B6 mice, perhaps resulting from the
delayed clearance in the liver.
Inhibition of the OAS-RNase L Pathway Is Required for
the Induction of Hepatitis
Viral replication in the liver is associated with induction of hepa-
titis. Indeed, necrotic foci and parenchymal inflammation were
observed in liver sections from A59 infected B6 mice sacrificed
at 5 d.p.i. (Figures 7A and 7B). Similar pathology was observed
in sections from A59- or ns2-H126-infected RNase L/ mice
at 5 d.p.i., while liver sections from ns2-H126R-infected B6
mice, exhibited no obvious pathological changes (Figure 7A).
However, as might be predicted by the lack of viral clearance
from the livers of RNase L/mice, there was extensive necrosis
and inflammation in A59- or ns2-H126R-infected livers from
RNase L/ mice compared with the few necrotic foci in the
A59-infected livers and the absence of pathology in ns2-
H126R-infected livers from B6 mice at 7 d.p.i. (Figure 7A).
Consistent with the pathology, staining with anti-caspase-3 anti-
body demonstrated extensive apoptosis around necrotic foci in
A59-infected livers from both B6 and RNase L/ mice, but only
in livers of RNase L/mice infectedwith ns2-H126R (Figure 7B).
Inflammation in the liver is associatedwith the local production
of inflammatory cytokines, especially TNF-a and IFN-g (Das
et al., 2009). The patterns of cytokine mRNAs induced by A59
and ns2-H126R were consistent with the levels of necrosis and
inflammation observed above. There were no differences in the607–616, June 14, 2012 ª2012 Elsevier Inc. 611
Figure 6. MHV ns2 Enhances Virus Replica-
tion In Vivo by Inhibiting RNase L Signaling
(A) Four-week-old B6 or RNase L/ mice were
inoculated intrahepatically with A59 or ns2-H126R
(200 PFU/mouse). At 3, 5, and 7 d.p.i., organswere
harvested and homogenized, and virus titers were
determined. The dashed line represents the limit of
detection and the error bars represent the SEM
(n = 5). Asterisks indicate that differences are
statistically significant (*p < 0.05 and ***p < 0.001).
(B) Liver sections from mice sacrificed at 5 d.p.i.
were stained with anti-MHV N monoclonal anti-
body. The scale bar represents 200 mm. Sections
are representative of two sections from each of
three animals from each group.
See also Figure S3.
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infected B6 and RNase L/ mice at 3 and 5 d.p.i., while
ns2-H126R induced only minimal levels of both cytokines in
livers of B6 mice. A59 and ns2-H126R induced similar levels of
TNF-a and IFN-g mRNAs in the livers of RNase L/ mice (Fig-
ure 7C), indicating, as expected, that ns2-H126R induced the
same extent of hepatitis as A59, in the absence of expression
of the OAS-RNase L pathway. However, there was a significantly
higher (p = 0.0308) level of expression of IFN-gmRNA in the liver
of RNase L/ mice compared with B6 mice at 7 d.p.i., consis-
tent with the increased virus titers (Figure 6A) and necrosis
(Figure 7A).
DISCUSSION
We present evidence for a molecular mechanism of subversion
of the RNase L pathway in macrophages that regulates acute
hepatitis during MHV infection. MHV and other closely related612 Cell Host & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier Inc.betacoronaviruses (de Groot et al.,
2012) encode ns2 proteins that together
with related proteins of toroviruses and
human rotavirus form a protein family
(known also as LigT-like or family II) with
cellular proteins of diverse origins, some
of which possess cyclophosphodiester-
ase (CPD) activity. The family is part of
a larger superfamily of 2H phosphodies-
terases characterized by the presence
of a pair of conserved His-x-Thr/Ser
motifs (Mazumder et al., 2002; Snijder
et al., 2003). We were unable to demon-
strate that ns2 has a CPD activity using
as substrates 20,30 cAMP, 30,50 cAMP,
and ADP-ribose 100,200 cyclic phosphate
(unpublished data), but instead found
that ns2 is a 20,50-phosphodiesterase
cleaving, and thus eliminating, 2-5A, the
activator of RNase L. In this respect, ns2
resembles the E. coli 20-50-RNA ligase,
also within the 2H phosphodiesterase
superfamily, which can ligate 20,50 link-
ages of the noncognate tRNA splicingintermediates and is also able to carry out the reverse 20,50-phos-
phodiesterase reaction in vitro (Arn and Abelson, 1996). Before
this study, 20-PDE (PDE12) of the different exonuclease-endonu-
clease-phosphatase family (Goldstrohm and Wickens, 2008)
was the only mammalian enzyme known that cleaves the 20,50
bond in 2-5A. Accordingly it was proposed to be a key regulator
of the OAS/RNase L system (Kubota et al., 2004). Thus, two
proteins, 20-PDE and ns2, both of which can cleave 2-5A,
evolved independently. It remains to be seen whether other
incompletely characterized homologs of ns2 of the viral and
cellular origins have similar substrate specificity.
Substitution of the catalytic His residue (H126R) of ns2 abro-
gated phosphodiesterase activity in vitro (Figure 5) aswell as virus
replication inmacrophagesand in the liversofB6mice (Zhaoetal.,
2011), demonstrating that the enzymatic activity of ns2 was
necessary for the type I IFN antagonism and virulence conferred
by ns2. Two additional ns2mutant viruses, one with H46A substi-
tution of the second predicted catalytic His residue (Roth-Cross
Figure 7. MHV ns2 Facilitates the Induction of Viral Hepatitis in vivo
(A) Livers sections frommock or virus-infected mice sacrificed at 5 and 7 d.p.i.
were stained with hematoxylin and eosin (H&E). Arrows show areas of
necrosis. The scale bar represents 500 mm. Sections are representative of two
sections from three animals from each group.
(B) Liver sections from mice sacrificed at 5 d.p.i. were stained with H&E for
detection of inflammation or with anti-caspase-3 antibody for detection of
apoptosis. The scale bars represent 100 mm. Sections are representative of
two sections from three animals from each group.
(C) Livers were harvested frommock- or virus-infected mice (n = 5) at 3, 5, and
7 d.p.i., and RNA was isolated. TNF-a and IFN-g mRNAs were quantified by
qRT-PCR, normalized to b-actin mRNA level, and expressed as the fold
change relative to mock infected with the formula 2D[DCT].The error bars
represents the SEM. Asterisks indicate that differences are statistically
significant (*p < 0.05).
See also Table S1.
Cell Host & Microbe
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2005), displayed similar phenotypes to ns2-H126R (Figure S1).
These data confirm the crucial roles of His126 and His46, each
within conserved His-x-Thr/Ser motifs in enzymatic activity.
Viruses have evolved multiple mechanisms for inhibiting
RNase L. Thus, the susceptibility to RNase L in vitro and inCell Hmice varies among viruses and cell types (Silverman, 2007;
Zhou et al., 1997). HIV (Martinand et al., 1999) and EMCV (Marti-
nand et al., 1998) induce expression of an RNase L inhibitor
protein, RLI (a.k.a. ABCE1). However, RLI is apparently less effi-
cient than ns2 in the control of RNase L activity during EMCV
infections (Figure 2). The group C enterovirus genome contains
a conserved RNA structure that inhibits the activity of RNase L
(Townsend et al., 2008). Herpes simplex virus I (Cayley et al.,
1984) and SV40 (Hersh et al., 1984) induce synthesis of 2-5A
derivatives that antagonize or fail to activate RNase L. Vaccinia
E3L protein antagonizes OAS by reducing the level of dsRNA
available and successfully escapes the effects of RNase L (Xiang
et al., 2002). Based on the finding that the A59 nucleocapsid (N)
protein could functionally replace the E3L protein in rescuing
vaccinia virus DE3L from the antiviral effects of IFN it was sug-
gested that N could also bind dsRNA, thus interfering with the
activation of OAS (Ye et al., 2007). However, expression of N
protein, in the context of MHV infection, is clearly not potent
enough to shut down OAS-RNase L pathway as ns2-H126R
induces RNase L-mediated cleavage of rRNA in BMMs (Fig-
ure 4A). In contrast, rRNA cleavage was not detectable in A59 in-
fected BMMs, providing further evidence that ns2 is a potent
antagonist of the OAS-RNase L pathway. The comparable level
of A59 replication in B6 and RNase L/ BMMs and in the in-
fected liver at least through 5 d.p.i. suggests that ns2 is able to
completely antagonize RNase L activity, although there may be
cell types in which this is not complete. Our findings demonstrate
amechanism bywhich the OAS-RNase L pathway can be antag-
onized, that is by blocking the activation of RNase L through the
ns2-mediated cleavage of 2-5A.
Interestingly, while there were no significant differences in viral
titers or pathology in the livers of A59-infected B6 and RNase
L/ mice during early infection, by 7 d.p.i., a time at which virus
is nearly cleared from B6 mice, the livers of infected RNase L/
mice still had significant titers of virus, antigen expression and
pathology (Figures 6 and 7), implying that RNase L/ mice are
defective in viral clearance. One possible reason for the delay
in clearance is that RNase L/ mice have lower levels of
apoptosis and in addition are relatively resistant to apoptosis, re-
sulting in increased numbers of cells in the thymus and spleen
(Zhou et al., 1997). Indeed, we observed increased virus titers
in the spleen of infected RNase L/ mice compared to B6
mice even at 3 d.p.i. (Figure 6A). This could potentially confer
defects in adaptive immune responses; the T cell response,
responsible for viral clearance, peaks at 7 d.p.i., the time at
which differences in RNase L/ and B6 mice infections are
detectable. RNase L/ mice were, however, eventually able to
clear virus; there was no detectable infectious virus, viral RNA,
N protein or pathology in the liver by 30 d.p.i. (Figure S3B). The
requirement for basal RNase L activity in the timely clearance
of MHV is under investigation.
The replication of ns2-H126R was attenuated in macrophage
lineage cells, but not in other primary cells or transformed cell
lines (Zhao et al., 2011), indicating that the OAS-RNase L
pathway is targeted by ns2 specifically in macrophages. This
correlates with basal levels of ISGs and MHV-induced IFN
production, which differs among cell types, with the highest
expression in macrophages (Ida-Hosonuma et al., 2005; Zhou
et al., 1997). Accordingly, we found that the basal levels ofost & Microbe 11, 607–616, June 14, 2012 ª2012 Elsevier Inc. 613
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(Kakuta et al., 2002), OAS1a, OAS2, and OAS3, were also higher
in macrophages as compared with primary hepatocytes (data
not shown) (Asada-Kubota et al., 1998). We hypothesize that
Kupffer cells serve as a gateway to restrict entrance from the
sinusoids into the liver parenchyma. Indeed, it has been reported
that IFN signaling in macrophages is crucial for control of hepa-
titis induced byMHV (Cervantes-Barraga´n et al., 2009) as well as
by LCMV (Lang et al., 2010). We propose that upon infection
of Kupffer cells, the IFN response, most importantly the OAS-
RNaseL pathway, creates an antiviral state restricting infection
and limiting spread of virus to the parenchymal hepatocytes,
thus preventing hepatitis. However, ns2 facilitates viral replica-
tion in Kupffer cells by antagonizing the OAS-RNase L pathway,
thus downregulating the IFN response and enhancing entry into
the liver parenchyma. Depletion of macrophages confers
susceptibility to ns2-H126R as well as increased susceptibility
to A59 (Zhao et al., 2011), supporting the notion that the Kupffer
cells provide protection against invasion of the liver parenchyma.
After intracranial inoculation, ns2 mutants replicate to the
same titers as A59 in the brains of B6 (Roth-Cross et al., 2009)
and RNase L/ mice (data not shown), implying that antago-
nism of RNase L is not required for efficient MHV replication in
the brain. However, we found that clearance is delayed in the
brains (data not shown) as in the livers (Figure 6A) of RNase
L/ mice. Similarly, the MHV-JHM v-2.2 variant replicated to
a similar titer in the CNS during acute infection of B6 and
RNaseL/ mice; however, v-2.2 spread into microglia/macro-
phages within the gray matter of the spinal cord and induced
more demyelination in RNase L/ mice than in B6 mice (Ireland
et al., 2009). (While there are no published data on ns2 expres-
sion by v-2.2, it is very likely to express an active ns2 as the
closely related JHM.SD encodes an ns2 capable of inhibiting
RNase L in vitro [data not shown].) These findings support our
previous conclusion that the requirement for ns2 expression for
MHV virulence is organ specific (Zhao et al., 2011); they also
show that basal levels of RNase L expression are required for effi-
cient MHV clearance in the brain as well as the liver (Figure 6).
Our results underscore the important role of RNase L in host
restriction of viral infection of the liver. The success of IFN-a treat-
ment of chronic hepatitis C virus (HCV)may depend in part on the
susceptibility of viral RNA genome to degradation by RNase L,
which cleaves single-stranded viral RNA on the 30 sides of UU
and UA dinucleotides. Cleavage of HCV genome RNA by RNase
L releases a small RNA that is recognized by RIG-I and thus
serves to enhance IFN induction (Malathi et al., 2010). Indeed,
the strains of HCV that are most susceptible to IFN-a treatment
are those strains with genomes predicted to be most vulnerable
to RNase L-mediated degradation (Han et al., 2004; Washen-
berger et al., 2007). Thus, enhancement of the activity of the
OAS-RNase L pathway may have potential for antiviral therapy
for liver infections. A possible approach to enhancing RNase L
mediated viral RNA genome degradation might be to limit activ-
ities of enzymes that degrade 2-5A; treatment with an inhibitor
for 20-PDE was shown to decrease vaccinia virus replication
in vitro (Kubota et al., 2004). In this regard, inhibitors of virus-
encoded phosphodiesterases that degrade 20,50-oligoadeny-
lates could provide an avenue for development of targeted
antiviral drugs.614 Cell Host & Microbe 11, 607–616, June 14, 2012 ª2012 ElsevierEXPERIMENTAL PROCEDURES
Cell Lines, Viruses, and Mice
Murine L2 fibroblast and HEK293T cells were cultured as described previously
(Roth-Cross et al., 2007). Plaque assays were performed on murine L2 cell
monolayers (Hingley et al., 1994). Recombinant coronaviruses inf-MHV-A59
(A59) and inf-ns2-H126R (ns2-H126R) have been described previously
(Roth-Cross et al., 2009; Schwarz et al., 1990). (See the Supplemental Exper-
imental Procedures for other ns2 mutants.) EMCV (Babu et al., 1985) was ob-
tained from Dr. Sally Huber (University of Vermont), and Sendai virus (SeV),
strain 52 (Lo´pez et al., 2006), was obtained from Dr. Carolina Lopez (University
of Pennsylvania). C57BL/6 (B6) mice were purchased from Jackson Labora-
tory. RNase L/ mice (B6, ten generations of backcrossing) (Zhou et al.,
1997) were bred in the University of Pennsylvania animal facility. PKR/
mice (B6 background) (Yang et al., 1995) were a gift from Bryan R.G. Williams
(Monash Institute, Melbourne).
Plasmid Constructs
The ns2 and ns2-H126R open reading frames were ligated into mammalian
expression vector pCAGGS, resulting in pC-ns2 and pC-ns2-H126R. The
ns2 and ns2-H126R open reading frames (ORFs) were inserted into E. coli
expression vector pMAL-c2, resulting in pMAL-ns2 and pMAL-ns2-H126R.
The murine 20-PDE-ORF cloned into pET-SUMO was obtained from Reinhard
Seidlmeier, Ingenium Pharmaceuticals AG, Martinsried, Germany.
BMM Isolation and Infection
Primary BMMs were generated from the hind limbs of B6 or RNase L/ mice
as described previously (Caaman˜o et al., 1999) and cultured in DMEM supple-
mented with 10% FBS and 20% L929 cell-conditioned medium for 6 days.
BMMs were either mock infected or infected with 0.01 or 1 plaque forming
units (PFU)/cell with A59 or ns2-H126R and harvested at time points indicated.
Real-Time Quantitative RT-PCR
RNA was isolated with an RNeasy mini kit (QIAGEN). Quantitative RT-PCR
(qRT-PCR) was performed with an iQ5 iCycler (Bio-Rad), and cycle threshold
(CT) values were recorded as described previously (Rose et al., 2010; Roth-
Cross et al., 2007). Viral mRNA levels were expressed as relative to b-actin
mRNA with the formula 2DCT (DCT = CT(gene of interest) – CT(b-actin)). Cytokine
mRNA expression levels were expressed as the fold change relative to
mock-infected levels with the formula 2D(DCT). The primers used in qRT-PCR
are listed in Table S1.
RNase L-Mediated Ribosomal RNA Cleavage in Intact Cells
For quantification of rRNA cleavage, total RNA from virus-infected BMMs or
transfected 293T cells (see the Supplemental Experimental Procedures) was
isolated with the RNeasy kit (QIAGEN) and quantified by Nanodrop analyzer.
Equal quantities of RNA (500 ng) were separated on RNA chips and analyzed
with an Agilent Bioanalyzer 2100 (Agilent Technologies) (Xiang et al., 2003).
Quantification of 2-5A
2-5Awas quantified by an indirect assay in which activation of RNase L activity
is measured (Elbahesh et al., 2011). In brief, cells were lysed in preheated
(95C) buffer containing 1% Nonidet-P40 and clarified by centrifugation,
and molecules >3 kDa were removed by centrifugation in Microcon filters
(Millipore). RNase L activity was determined with a FRET assay, with recombi-
nant human RNase L and a cleavable substrate consisting of a 36 nucleotide
synthetic oligoribonucleotide [50(6-FAMUUAUCAAAUUCUUAUUUGCCCCA
UUUUUUUGGUUUA-BHQ-1)-30] derived from respiratory syncytial virus
(Thakur et al., 2005). A standard curve was generated with authentic trimer
2-5A, (20-50)p3A3 (95% purity), and fluorescence was measured with a Wallac
1420 fluorimeter (Perkin-Elmer LAS).
20-PDE Activity Assay
20-PDE activity was quantified by monitoring of the degradation of purified
(20-50)p3A3 with HPLC (Molinaro et al., 2006) or the FRET-based RNase L
activity assay, as above (Thakur et al., 2005) (see the Supplemental Experi-
mental Procedures). For the 2-5A degradation assay, 100 mM purified
(20-50)p3A3 was incubated for the indicated time with 10 mg/ml purified ns2,Inc.
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filter MWCO 3kDa (Millipore). The filtrate was diluted 1:5 and loaded onto
a Dionex P100 analytical HPLC column, interfaced with Beckman System
Gold HPLC system connected to a 32 Karat workstation. The chromatograms
were analyzed with 32 Karat software (Beckman-Coulter).
Infection of Mice
Four- to five-week-old B6 or RNase L/ mice were anesthetized with isoflur-
ane (IsoFlo, Abott Laboratories) and inoculated intrahepatically with A59 or
ns2-H126R (200 PFU) in 50 ml PBS containing 0.75% BSA. At 3, 5, and 7
d.p.i., animals were sacrificed, livers, spleens, lungs, and kidneys were
harvested, and viral titers in lysates were determined by plaque assay
(Gombold et al., 1993). Alternatively, organs were used for RNA isolation or
immunohistochemistry.
This study was carried out in strict accordance with the Guide for the Care
and Use of Laboratory Animals and the Public Health Service Policy on
Humane Care and Use of Laboratory Animals. The protocol was approved
by the University of Pennsylvania’s Institutional Animal Care and Use
Committee (permit number A3079-01).
Histology and Immunohistochemistry
Livers were fixed overnight in 4% paraformaldehyde, embedded in paraffin
and sectioned. Sections were stained with hematoxylin and eosin or alterna-
tively blocked with 10% normal donkey serum and immunostained with
a 1:20 dilution of a monoclonal antibody against MHV nucleocapsid (N) protein
or a 1:1000 dilution of polyclonal antibody against caspase-3 antibody.
Staining was developed using avidin-biotin-immunoperoxidase (Vector
Laboratories).
Statistical Analysis
An unpaired two-tailed t test was used to determine statistical significance.
Data were analyzed with GraphPad Prism software (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
doi:10.1016/j.chom.2012.04.011.
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